CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

back to search results

c-Myc [EP121]

Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: EP121
Host: Rabbit
Isotype: IgG
Application: Immunohistochemistry (IHC)
Application notes: Prediluted
Conjugation Type: Unconjugated
Reactivity: Human
General notes: Localization: nucleus.
Buffer: EDTA pH8.0
UNSPSC code: 12352203

The c-MYC gene is located at chromosome 8q24. It is required for progression through the cell cycle and promotes cellular proliferation. The t(8;14)(q24;q32) translocation and the c-MYC/immunoglobulin heavy-chain (IGH) fusion gene are not only in Burkitt lymphoma, but are also seen in diffuse large B-cell lymphoma, blastic mantle cell lymphoma and transformed follicular lymphoma. In another study on predicting c-MYC translocation in 17 cases of Burkitt lymphomas (BLs) and 19 cases of diffuse large B-cell lymphomas (DLBCLs), Ruzinova et al. reported that the sensitivity and specificity of this c-Myc antibody on identifying tumor harboring a c-MYC rearrangement reached 96% and 90% respectively. This novel c-Myc antibody is a useful tool for identifying aggressive B-cell lymphomas likely to harbor a c-MYC rearrangement, and thus warrant genetic testing (Shipping Cost: €200.00)

c-Myc [EP121]

The c-MYC gene is located at chromosome 8q24. It is required for progression through the cell cycle and promotes cellular proliferation. The t(8;14)(q24;q32) translocation and the c-MYC/immunoglobulin heavy-chain (IGH) fusion gene are not only in Burkitt lymphoma, but are also seen in diffuse large B-cell lymphoma, blastic mantle cell lymphoma and transformed follicular lymphoma. In another study on predicting c-MYC translocation in 17 cases of Burkitt lymphomas (BLs) and 19 cases of diffuse large B-cell lymphomas (DLBCLs), Ruzinova et al. reported that the sensitivity and specificity of this c-Myc antibody on identifying tumor harboring a c-MYC rearrangement reached 96% and 90% respectively. This novel c-Myc antibody is a useful tool for identifying aggressive B-cell lymphomas likely to harbor a c-MYC rearrangement, and thus warrant genetic testing